Our PEL team will contact you by email or phone within one business day, based on the contact option you selected.
If you selected an email contact, be sure to check your spam folder for an email from [email protected] if you don’t find it in your inbox.
Your PEL will discuss questions, cover basic study eligibility, and provide information about current and future study opportunities.
If you meet the initial eligibility criteria, your PEL will connect you to an appropriate study site.
Your PEL will also ask permission to contact you in the future regarding any changes to current studies or future clinical or nonclinical research opportunities.
Patient portrayal.
Wherever you are on your journey, there is always something new to learn. At the Ultragenyx Patient Advocacy site and our Facebook community page, you will meet a welcoming community of individuals on similar paths.
You will also find countless resources and tools. Read patient stories, hear about upcoming events, learn where to locate a patient group, and realize that you are not alone.
Ultragenyx is not responsible for the content or privacy policies of third-party websites outside of its control. Content from Ultragenyx Patient Advocacy (ultrarareadvocacy.com) is intended for a U.S. patient and caregiver audience. Content from the Ultragenyx corporate website (ultragenyx.com) is intended for investors and the general public within the U.S. The information provided on these Ultragenyx sites may not apply to your country. Please contact your physician to learn more about these topics. Thank you for visiting our Clinical Trial site. We hope your visit was informative and enjoyable.
Do you wish to continue?